Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.56 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.56 |
| ▸ | PDE8A | O60658 | 3/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837787 | 0.85 | PDE7A (0.58) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100389 | 0.85 | PDE7A (0.58) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL136525 | 0.83 | PDE7A (0.53) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100455 | 0.81 | PDE7A (0.63) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL101113 | 0.78 | PDE7A (0.82) | PDE7APDE7BPDE8AS1PR1 | |
| SCHEMBL30837887 | 0.77 | PDE7A (0.77) | PDE7APDE7BPDE8AS1PR1 | |
| SCHEMBL100689 | 0.77 | PDE7A (0.77) | PDE7APDE7BPDE8AS1PR1 | |
| SCHEMBL101209 | 0.76 | PDE7A (0.59) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL100290 | 0.74 | PDE7A (0.66) | PDE7APDE7BPDE8AS1PR1S1PR5 | |
| SCHEMBL30837851 | 0.74 | PDE7A (0.66) | PDE7APDE7BPDE8AS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | PDE7A 1520/4885PDE7B 1364/4885PDE8A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.